Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration ...

TG Therapeutics has started enrolling adults with relapsing forms of MS for a Phase 3 trial testing a subcutaneous ...

Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic ...

Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window MILAN -- An ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & ...

--The world's first and only wearable, disposable automatic delivery system for self-administration of drugs with dose volumes 5mL or larger --Now available to pharmaceutical companies for use in drug ...

The anti-amyloid maintenance therapy offers a once-weekly, subcutaneous option after 18 months of intravenous treatment.

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and ...

Leqembi IQLIK, a subcutaneous version of Leqembi, will launch on Oct. 6, 2025, with a list price of $375 per autoinjector.